Allen Roses Discusses Ability of GWAS to Detect ADRs; GSK’s Abacavir is First Up

Roses, one of the study’s authors and the former head of genetics research at GlaxoSmithKline, discusses what GSK’s genome-wide screening study with abacavir means for the design and conduct of future studies trying to determine the appropriate patient population for a drug before it hits the market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.